About Careers MedBlog Contact us

Compound Shows Promise for Auto-Immune Disease

by Himabindu Venkatakrishnan on February 17, 2015 at 9:31 AM
Font : A-A+

 Compound Shows Promise for Auto-Immune Disease

Combating arthritis, multiple sclerosis, gout and other auto-immune diseases could be possible with two compounds - one naturally derived from fasting and another from intensive exercise, said researchers on Monday.

The compounds throw a wrench into a molecular mechanism that causes inflammation, a driver of these diseases, the teams reported in Nature Medicine.


Called beta-hydroxybutyrate (BHB) and MCC950, the compounds may open up an intriguing avenue in drug research, they said.

The hope is that the mechanism they target, NLRP3, proves to be common to all auto-immune diseases, regardless of which part of the body is affected.

"Drugs like aspirin or steroids can work in several diseases, but can have side effects or be ineffective," said Luke O'Neill, a biochemistry professor at Trinity College Dublin, whose team worked with Australian scientists on MCC950.

"What we have found is a potentially transformative medicine, which targets what appears to be the common disease-causing process in a myriad of inflammatory diseases."

BHB was found separately by researchers at the Yale School of Medicine.

It is a metabolite -- a product of metabolism that results from fasting, high-energy exercise or the low-carb "ketogenic" diet.

So far, the compounds have lowered inflammation in mice with multiple sclerosis, a condition called Muckle-Wells syndrome and familial cold auto-inflammatory disease -- fever and joint pain that occur after exposure to cold temperatures.

Years of trials will be needed to see if they work on humans and are safe.

Source: AFP


Recommended Reading

Latest Drug News

 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
 New Ray of Hope for Atrial Fibrillation Patients With Kidney Disease
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Compound Shows Promise for Auto-Immune Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests